FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783261636> ?p ?o ?g. }

• W2783261636 abstract "The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug concentrations in normal brain. This study was conducted to evaluate if activation of A2A receptors would increase intra-tumoral temozolomide concentrations in patients with glioblastoma. Patients scheduled for a clinically indicated surgery for recurrent glioblastoma were eligible. Microdialysis catheters (MDC) were placed intraoperatively, and the positions were documented radiographically. On post-operative day #1, patients received oral temozolomide (150 mg/m2). On day #2, 60 min after oral temozolomide, patients received one intravenous dose of regadenoson (0.4 mg). Blood and MDC samples were collected to determine temozolomide concentrations. Six patients were enrolled. Five patients had no complications from the MDC placement or regadenoson and had successful collection of blood and dialysate samples. The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson. The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson. The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively. Peak concentration and Tmax in brain were not significantly different. Although previously shown to be efficacious in rodents to increase varied size agents to cross the BBB, our data suggest that regadenoson does not increase temozolomide concentrations in brain. Further studies exploring alternative doses and schedules are needed; as transiently disrupting the BBB to facilitate drug entry is of critical importance in neuro-oncology." @default.
• W2783261636 created "2018-01-26" @default.
• W2783261636 creator A5002837753 @default.
• W2783261636 creator A5003196589 @default.
• W2783261636 creator A5010420312 @default.
• W2783261636 creator A5011587382 @default.
• W2783261636 creator A5014542869 @default.
• W2783261636 creator A5015341987 @default.
• W2783261636 creator A5019250130 @default.
• W2783261636 creator A5021815921 @default.
• W2783261636 creator A5033894193 @default.
• W2783261636 creator A5064627876 @default.
• W2783261636 creator A5079418869 @default.
• W2783261636 creator A5082260690 @default.
• W2783261636 creator A5087778827 @default.
• W2783261636 date "2018-01-15" @default.
• W2783261636 modified "2023-10-15" @default.
• W2783261636 title "The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma" @default.
• W2783261636 cites W1485411688 @default.
• W2783261636 cites W1551550807 @default.
• W2783261636 cites W1577346867 @default.
• W2783261636 cites W1868995267 @default.
• W2783261636 cites W1953042185 @default.
• W2783261636 cites W1963542743 @default.
• W2783261636 cites W1966720603 @default.
• W2783261636 cites W1968054359 @default.
• W2783261636 cites W1976723283 @default.
• W2783261636 cites W1986341106 @default.
• W2783261636 cites W2012681969 @default.
• W2783261636 cites W2014475188 @default.
• W2783261636 cites W2035833975 @default.
• W2783261636 cites W2068656699 @default.
• W2783261636 cites W2073630530 @default.
• W2783261636 cites W2080308953 @default.
• W2783261636 cites W2087881873 @default.
• W2783261636 cites W2096287682 @default.
• W2783261636 cites W2134466068 @default.
• W2783261636 cites W2143935367 @default.
• W2783261636 cites W2144500288 @default.
• W2783261636 cites W2147809951 @default.
• W2783261636 cites W2154451644 @default.
• W2783261636 cites W2159821105 @default.
• W2783261636 cites W2162965771 @default.
• W2783261636 cites W2168634451 @default.
• W2783261636 cites W2185908114 @default.
• W2783261636 cites W2202001486 @default.
• W2783261636 cites W2278495018 @default.
• W2783261636 cites W2333603774 @default.
• W2783261636 cites W2337076198 @default.
• W2783261636 cites W2400311982 @default.
• W2783261636 cites W2561872017 @default.
• W2783261636 cites W2562643097 @default.
• W2783261636 cites W2568405449 @default.
• W2783261636 cites W2596148163 @default.
• W2783261636 cites W2596856888 @default.
• W2783261636 cites W2766048952 @default.
• W2783261636 cites W90904735 @default.
• W2783261636 doi "https://doi.org/10.1186/s12987-017-0088-8" @default.
• W2783261636 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5767971" @default.
• W2783261636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29332604" @default.
• W2783261636 hasPublicationYear "2018" @default.
• W2783261636 type Work @default.
• W2783261636 sameAs 2783261636 @default.
• W2783261636 citedByCount "52" @default.
• W2783261636 countsByYear W27832616362019 @default.
• W2783261636 countsByYear W27832616362020 @default.
• W2783261636 countsByYear W27832616362021 @default.
• W2783261636 countsByYear W27832616362022 @default.
• W2783261636 countsByYear W27832616362023 @default.
• W2783261636 crossrefType "journal-article" @default.
• W2783261636 hasAuthorship W2783261636A5002837753 @default.
• W2783261636 hasAuthorship W2783261636A5003196589 @default.
• W2783261636 hasAuthorship W2783261636A5010420312 @default.
• W2783261636 hasAuthorship W2783261636A5011587382 @default.
• W2783261636 hasAuthorship W2783261636A5014542869 @default.
• W2783261636 hasAuthorship W2783261636A5015341987 @default.
• W2783261636 hasAuthorship W2783261636A5019250130 @default.
• W2783261636 hasAuthorship W2783261636A5021815921 @default.
• W2783261636 hasAuthorship W2783261636A5033894193 @default.
• W2783261636 hasAuthorship W2783261636A5064627876 @default.
• W2783261636 hasAuthorship W2783261636A5079418869 @default.
• W2783261636 hasAuthorship W2783261636A5082260690 @default.
• W2783261636 hasAuthorship W2783261636A5087778827 @default.
• W2783261636 hasBestOaLocation W27832616361 @default.
• W2783261636 hasConcept C126322002 @default.
• W2783261636 hasConcept C146957229 @default.
• W2783261636 hasConcept C170493617 @default.
• W2783261636 hasConcept C2776694085 @default.
• W2783261636 hasConcept C2777361974 @default.
• W2783261636 hasConcept C2777389519 @default.
• W2783261636 hasConcept C2778405248 @default.
• W2783261636 hasConcept C2778938600 @default.
• W2783261636 hasConcept C2780964509 @default.
• W2783261636 hasConcept C42219234 @default.
• W2783261636 hasConcept C71924100 @default.
• W2783261636 hasConcept C98274493 @default.
• W2783261636 hasConceptScore W2783261636C126322002 @default.
• W2783261636 hasConceptScore W2783261636C146957229 @default.
• W2783261636 hasConceptScore W2783261636C170493617 @default.
• W2783261636 hasConceptScore W2783261636C2776694085 @default.

• next